As part of our ongoing aim to bring you reports of significant or innovative developments, we have added a review of a study on long-term evolocumab use in patients with established atherosclerotic cardiovascular disease.
Independent commentary is provided by Associate Professor John Amerena, a Cardiologist at Barwon Health, and director of the Geelong Cardiology Research Unit.
Please login below to download this issue (PDF)